What is the clinical evidence from this study?

Study design: Cohort. Population: Diabetes (MOD and SIRD subtypes) undergoing bariatric surgery (n=48). Intervention: Moderate obesity-related diabetes (MOD) subtype vs. Severe insulin-resistant diabetes (SIRD) subtype. Primary outcome: Changes in BMI, HbA1c, fatty liver index, insulin resistance, transaminases, and plasma lipids.

What does this research mean for the field?

Following bariatric surgery, patients with moderate obesity-related diabetes (MOD) achieve significant improvements in liver function and cardiovascular risk factors that are not observed in patients with severe insulin-resistant diabetes (SIRD), despite comparable weight loss and glycemic improvements. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The research aims to determine differences in outcomes between severe insulin-resistant diabetes (SIRD) and moderate obesity-related diabetes (MOD) after bariatric surgery.

June 7, 2026

2640-P: Role of Diabetes Subtypes for Reducing Modifiable Cardiovascular Risk Factors after Bariatric Surgery

Key Result

Following bariatric surgery, the MOD subtype showed significant improvements in transaminases, triglycerides (-22%), and LDL-cholesterol (-20%) compared to the SIRD subtype (all p<0.05).

Key Points

The research aims to determine differences in outcomes between severe insulin-resistant diabetes (SIRD) and moderate obesity-related diabetes (MOD) after bariatric surgery.
Participants were assigned to MOD (n=37) or SIRD (n=11) using a validated algorithm.
Anthropometric and laboratory data were collected before and 12 months after surgery.
Non-parametric testing was used for inter-cluster comparisons and paired testing for pre- and post-surgery differences.
Both MOD and SIRD experienced similar reductions in BMI (-28% for MOD vs. -33% for SIRD) and HbA1c (-19% for MOD vs. -23% for SIRD).
Only MOD showed significant improvements in transaminases and plasma lipids (e.g., -22% plasma triglycerides; p<0.05).
Fasting C-peptide decreased by 66% in SIRD with significant improvement in HOMA-IR from 9.5 to 1.5 a.u. (p<0.01).

Study Design

Type

Cohort (n=48)

Structured PICO

Does bariatric surgery improve cardiovascular risk factors and liver function differently in moderate obesity-related diabetes (MOD) compared to severe insulin-resistant diabetes (SIRD)?

Population

48 participants with moderate obesity-related diabetes (n=37) or severe insulin-resistant diabetes (n=11) evaluated before and 12 months after bariatric surgery.

Exposure

Bariatric surgery

Comparator

Comparison between diabetes subtypes (MOD vs. SIRD)

Outcome

Changes in anthropometric and laboratory data (BMI, HbA1c, liver lipid content, transaminases, plasma lipids, insulin resistance) at 12 months post-surgerysurrogate

Bariatric surgery yields similar weight loss and glycemic improvements across diabetes subtypes, but moderate obesity-related diabetes (MOD) derives greater benefits in liver function and lipid profiles compared to severe insulin-resistant diabetes (SIRD).

Abstract

Introduction and Objective: Phenotype-based clustering uncovered diabetes heterogeneity, but its relevance for tailored treatment remains unclear. The severe insulin-resistant diabetes subtype (SIRD) associates with steatotic liver disease, and higher cardiovascular risk, while moderate obesity-related diabetes (MOD) features mild metabolic alterations despite similar BMI. We examined whether SIRD and MOD exhibit different outcomes after bariatric surgery. Methods: Participants of the BARIA-DDZ study were assigned to MOD (n=37) or SIRD (n=11) using a validated algorithm (www.diabetescalculator.ddz.de). Anthropometric and laboratory data were measured before and 12 months after bariatric surgery. Non-parametric statistical testing was used to compare between clusters while paired testing was used to assess differences pre- and post-surgery within clusters. Results: Mean age was 48±6 years in MOD and 45±7 years in SIRD. Before surgery, MOD and SIRD had comparable BMI (all means, 48.5 kg/m2 vs. 46.8 kg/m2), HbA1c (6.6% vs. 7.0%) and liver lipid content (27.3% for MOD vs. 32.4%). After surgery, MOD and SIRD showed similar reductions in BMI (-28% vs. -33% for SIRD), HbA1c (-19% vs. -23% for SIRD), fatty liver index (both -25%) and insulin resistance (3fold rise in M-value; all p0.01) without differences between subtypes. However, only MOD featured also improvements in transaminases (-15% AST, -25% ALT, -52% GGT), plasma triglycerides (-22%) and LDL-cholesterol (-20%, all p0.05). In SIRD, changes in transaminases and plasma lipids were not statistically significant, while fasting C-peptide decreased by 66% as did HOMA-IR from 9.5 to 1.5 a.u. (both p0.01). Conclusion: Despite similar surgically-induced weight loss and HbA1c decrease, the MOD subtype shows additional improvements in liver function and cardiovascular risk factors compared to SIRD, suggesting a specific benefit for MOD which should be considered for referral to bariatric surgery. Disclosure O. Zaharia: None. C. Binsch: None. S. Trenkamp: None. J. Pützer: None. G. Xourafa: None. M. Huttasch: None. P. Schrauwen: Consultant; Current; AstraZeneca. Research Support; Ended; Pfizer Inc., MedImmune. M. Schlensak: None. F.A. Granderath: None. M. Roden: Advisory Panel; Current; AstraZeneca, Boehringer Ingelheim International GmbH, Lilly, Madrigal Pharmaceuticals, Inc., Novo Nordisk, Sanofi, Echosens. S. Kahl: None. Funding MKW NRW; BMG; BMBF; DZD; EFRE-0400191, EUREKA Eurostars-2 (E! 113230 DIA-PEP); DFG, SFB 1116/2, GRK 2576; DDG).

AIに質問

Bookmark